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Abstract  
Objectives 
This study aimed to prospectively collect detailed clinical information for all enterovirus (EV) 
and human parechovirus (HPeV) meningitis cases in infants aged <90 days in the United 
Kingdom and Ireland.  
Participants, design and setting: 
Prospective, active national surveillance during July 2014/15 through the British Paediatric 
Surveillance Unit. Reporting paediatricians completed questionnaires requesting 
information on clinical presentation, investigations, management and outcomes at hospital 
discharge and after 12 months. 
Main Outcome Measures:  
To describe the clinical burden of EV and HPeV meningitis in infants aged <90 days. 
Results 
During the 13-month surveillance period, 703 cases (668 EV, 35 HPeV) were reported. The 
most common clinical presentations were fever (EV: 570/668 [85%]; HPeV: 28/35 [80%]), 
irritability (EV: 441/668 [66%]; HPeV: 23/35 [66%]) and reduced feeding (EV: 363/668 [54%]; 
HPeV 23/35 [66%]). Features of circulatory shock were present in 27% (182/668) of EV and 
43% (15/35) of HPeV cases. Overall, 11% (76/668) of EV and 23% (8/35) of HPeV cases 
required intensive care support.  Nearly all cases (678/703, 96%) were confirmed by 
cerebrospinal fluid (CSF) PCR, with 52% (309/600) having normal CSF white cell count for 
age. Two infants with EV meningitis died (2/668, 0.3%) and four survivors (4/666, 0.6%) had 
long-term complications at 12-months follow-up. Infants with HPeV meningitis survived 
without sequelae. 70% (189/270) had a formal hearing test, none had sensorineural hearing 
loss. 
Conclusion 
The incidence of laboratory-confirmed EV/HPeV meningitis in young infants is more than 
twice that for bacterial meningitis. Less than 1% will develop severe neurological 
complications or die of their infection. Further studies are required to formally assess long-
term neurodevelopmental sequelae.  
  
Introduction  
 
Hospitalisation rates for childhood viral meningitis in England have increased year-on-year 
over the past decade, reaching 70 per 100 000 children in 2011, with the highest rates 
reported in infants younger than 90 days (1). This trend coincides with increasing routine 
use of molecular assays such as polymerase chain reaction (PCR) testing for viral infections 
in local hospital laboratories, which has led to a seven-fold increase in reports of laboratory-
confirmed cases of viral meningo-encephalitis in the past decade (2). Enteroviruses (EV) 
accounted for half of nearly 10,000 reports and 92% of EV meningitis cases were reported in 
<3 month-olds (2). Human parechoviruses (HPeV) belong to the Picornaviridae family and 
can also cause viral meningo-encephalitis in infants, albeit less frequently than EV (3).  
 
EV and HPeV usually cause mild, self-limiting respiratory and gastointestinal infections in 
children. Occasionally, however, they may be responsible for more serious illness, including 
meningo-encephalitis, hepatitis, myocarditis or fulminant sepsis (4). Recent outbreaks 
associated with long-term neurological complications have been reported in Australia, 
northern Europe and USA (4–7). In neonates and young infants, viral meningitis can be 
difficult to diagnose and differentiate from more serious invasive bacterial infections 
because of their non-specific clinical presentation, especially in the early stages of illness 
(8,9), and lack of specific laboratory markers (10). Testing for EV/HPeV by clinicians and 
microbiologists across hospital laboratories is also variable because of differences in local 
protocols and limited understanding of clinical presentations, disease progression and 
outcomes. Additionally, there are no approved treatments for EV/HPeV infections and no 
investigational therapies undergoing clinical trials in Europe, in part due to lack of robust 
data to support the need for effective therapeutics.  The last UK publication on enterovirus 
epidemiology included retrospective data collected more than 20 years ago (11). We, 
therefore, undertook a prospective, population-based surveillance study to define the 
burden, clinical characteristics, investigations, management and outcomes of EV/HPeV 
meningitis in young infants across the UK and Republic of Ireland. 
 
Methods  
Surveillance 
This study was conducted by Public Health England (PHE) and St. George’s University of 
London through the British Paediatric Surveillance Unit (BPSU), a unique national clinical 
surveillance system set up to study rare diseases (12). The BPSU functions by sending 
paediatric consultants across the UK and Ireland a short electronic list of rare childhood 
conditions every month. All paediatricians are asked to respond and report whether they 
have seen a case (such as EV/HPeV meningitis) or confirm that they had no cases to report. 
Reporting is not compulsory but strongly encouraged, with regular reminders sent by the 
BPSU if no response is received. Following a positive report, the reporting paediatrician 
completes a detailed questionnaire on the case. 
 
The study began on 01 July 2014 and continued for 13 months. A case was defined as a 
hospitalised infant aged <90 days at diagnosis with laboratory-confirmed EV/HPeV 
meningitis with clinical features of meningitis (fever  38oC, coma, seizures, neck stiffness, 
apnoea, bulging fontanelle, irritability, lethargy, poor feeding) and laboratory confirmation 
of EV/HPeV from any site (CSF, blood, stool, throat, peri-anal swab). The Second Generation 
Surveillance System (SGSS), a national electronic reporting system used by NHS laboratories 
to notify clinically significant infections to Public Health England (PHE), was used as an 
alternative national data source for cases with EV/HPeV detected in the CSF in England, 
Wales and Northern Ireland. Additional cases identified through SGSS were followed-up in 
the same way as the BPSU-reported cases. Paediatricians who completed the clinical 
questionnaires were contacted after 12 months with a follow-up questionnaire on long-
term outcomes.  
 
Data analysis  
Data were entered into Microsoft Access and analysed using STATA 14.0 (StataCorp, College 
Station, Texas). Table 1 outlines a full list of clinical definitions. Annual incidence was 
calculated using published live-births for each of the nations in 2014 after adjustment for 
the 13-month surveillance period. Data are mainly descriptive and summarised as medians 
with interquartile ranges or proportions, and compared using the Mann Whitney U test or 
the Chi squared or Fisher exact test, respectively. The binomial method was used to 
calculate the 95% confidence intervals (CI) for proportions.  
 
Ethics Approval 
The study has been approved by the London Queen Square research ethics committee (Ref: 
14/LO/0229). 
 
Results 
During the 13-month surveillance period, 754 reports of EV/HPEV meningitis in infants aged 
<90 days were received and 703 (93%) fulfilled the case definition, including 668 (95%) with 
EV meningitis and 35 (5%) with HPeV meningitis. The number of cases peaked in summer 
(Fig 1). The annual incidence of EV meningitis was 0.79per 1,000 live-births and 0.04 per 
1,000 live-births for HPeV meningitis. EV serotype information was available for 67% 
(448/668) of cases and included echovirus (54%, 242/448), coxsackie B5 (7%, 32/448), 
coxsackie B4 (6%, 28/448) and enterovirus 71 (4%, 17/448). None of the HPeV strains were 
typed. 
 
The median age at diagnosis was 34 (IQR, 15 -53) days, and 58% (410/703 cases) were male. 
EV and HPeV cases were indistinguishable in terms of age distribution, clinical presentation 
and laboratory markers; none of the parameters were statistically significant (Fig 2). Among 
EV cases, fever (≥38C) was the commonest presentation (85%, 570/668), followed by 
irritability (66%, 441/668), reduced feeding (54%, 363/668) and lethargy (36%, 243/668). 
Fever was also the most common presentation in infants with HPeV meningitis (80%, 28/35) 
cases, followed by reduced feeding (71%, 25/35), irritability (66%, 23/35) and lethargy (51% 
18/35) (Fig 2). On examination, the most common finding was circulatory shock in 27% 
(182/668) of EV and 43% (15/35) of HPeV cases, followed by respiratory distress (EV, 12% 
[79/668]; HPeV, 26% [9/35]) and rash (EV, 24% [163/668]; HPeV, 29% [10/35]). Of note, 17% 
(6/35) of infants with HPeV meningitis had abdominal distension and 11% (4/35) had a 
reduced Glasgow Coma Scale (<11/15) at presentation.  
 
Intensive care admission 
Most EV cases were admitted to the paediatric ward (78%, 522/668) or short-term 
assessment unit (9%, 59/668), while 11% required admission to a paediatric intensive care 
(PICU; 7%, 46/668) or high dependency unit (HDU; 4%, 30/668). Of the 35 HPeV cases, 23% 
required PICU (17%, 6/35) or HDU (6%, 2/35) admission. Almost half the infants who 
presented in the first week of life (42%, 29/69) required PICU admission (Table 2). Half 
(50%, 23/46) the EV meningitis cases and all six HPeV cases in ICU required intubation and 
ventilation for a median of 5 and 4 days, respectively. A fifth (20%, 9/46) of EV meningitis 
cases and all HPeV cases required inotropic support. The most common EV serotypes 
responsible for PICU cases included echovirus 7 (n=4) and echovirus 9 (n=4), coxsackie B4 
(n=3), echovirus 11 (n=3) and enterovirus 71 (n=1). 
 
Diagnosis and investigation 
Nearly all reported cases (96%, 678/703) were diagnosed through detection of virus in the 
CSF. The virus was also identified in the stool in 10% (69/703), blood in 5% (38/703) and 
throat swabs in 5% (34/703). Of those with reported CSF results, half the EV (51%, 304/600) 
and all HPeV (100%, 29/29) meningitis cases had less than 20 white cells per mm3 in the CSF. 
Most cases also had a normal peripheral blood white cell counts (6-15 x109/L); EV: 85% 
(506/598) and HPeV: 56% (18/32). In addition, more than half the EV (56%, 360/643) and 
HPeV (67%, 22/33) cases had a CRP (C-reactive protein) level <10 mg/dL (Fig 2).  
 
Six infants had coagulase-negative Staphylococci (CoNS) isolated from blood cultures (n=5) 
or CSF (n=1); all were considered to be contaminants and not treated with antibiotics. 
 
In total, 8% (56/668) of EV and 29% (10/35) of HPeV meningitis cases had cranial ultrasound 
scans during admission. Relatively mild abnormalities were noted in five cases with EV 
meningitis (2 cases had resolving grade 1 IVH and 3 cases small choroid plexus bleeds with 
normal parenchyma). Overall, 3% (17/668) of EV meningitis cases had an MRI head scan 
during admission and eight were abnormal (white matter changes [n=3], and one case each 
of subdural haemorrhage, posterior fossa blood collection, acute infarct in the right corona, 
severe cystic encephalomalacia and mild ventricular dilatation).  
 
Treatment and outcomes at hospital discharge 
 A significant proportion of cases were treated with acyclovir in addition to empiric 
intravenous antibiotics (EV meningitis 27% 183/668; HPeV meningitis 46%, 16/35). The 
median duration of acyclovir treatment was 3.1. days. Three EV and one HPeV cases were 
also treated with intravenous immunoglobulin; the indication for administering 
immunoglobulin was not stated. Two infants with EV meningitis died (2/668; case fatality 
rate, 0.3%; 95% CI, 0.04-1.1%). Of the survivors, two had significant neurological sequelae at 
hospital discharge, which were still present at 12 months follow-up (Table 2). None of the 
infants with HPeV meningitis died and one had transaminitis at hospital discharge, which 
resolved spontaneously. Prematurity status, age at diagnosis and EV serotype were not 
associated with more severe clinical presentation or poor outcome at discharge. 
 
Follow-up at 12 months  
Follow-up questionnaires were sent to all paediatricians who had reported a case. In total, 
38% (254/668) of EV and 46% (16/35) HPeV infants were reviewed by the clinical team on at 
least one occasion during 12 months after hospital discharge. Of these, 70% (189/270) had a 
formal hearing test after discharge from hospital and none of those tested had 
sensorineural hearing loss. At follow-up, two additional infants with EV meningitis, who 
were well at discharge, were identified with neurological complications by 12 months. The 
risk of long-term sequelae among infants with EV meningitis who were followed up was 
0.6% (4/666; 95% CI, 0.2-1.5%) (Table 3). 
 
Discussion  
We have reported the largest prospective national study to evaluate the burden, clinical 
characteristics and outcomes of EV/HPeV meningitis in young infants during a period devoid 
of local or national outbreaks. We found some evidence of more severe disease in infants 
with HPeV compared to EV meningitis, with higher rates of circulatory failure, PICU 
admission and requirement for multi-organ support. Two of the 668 infants with EV 
meningitis died and four others had long-term neurodevelopmental complications at 12 
months follow-up, while the small number of infants with HPeV meningitis recovered 
without complications 
 
The incidence of laboratory-confirmed EV/HPeV meningitis is >2-fold higher than recent 
estimates for bacterial meningitis in the same age-group (0.38/1000 live births) using the 
same surveillance methodology (13). This incidence is also >5 times higher than group B 
streptococcal meningitis, currently the single most important cause of bacterial meningitis 
in young infants (13). Our estimates are, however, likely to be significantly under-estimated 
for several reasons. Infants with EV/HPeV meningitis often have normal peripheral white 
cell counts and CRP levels, which can reassure clinicians against further investigations. Even 
when lumbar puncture is performed, more than half do not exhibit CSF pleocytosis, and, 
therefore, may not undergo further testing for viruses (8). Many hospital laboratories only 
test CSF samples for viruses in the presence of CSF pleocytosis and negative bacterial 
cultures. As multiplex PCR-testing becomes more established, however, laboratories are 
increasingly testing all CSF samples routinely for viruses, especially in infants. This in part 
explains the rapidly increasing reports of EV/HPeV infections in England in recent years (2).  
 
Another major consideration is that 96% of cases were diagnosed through virus detection in 
the CSF. Paediatricians need to be aware that some of these viruses may only be detected at 
a peripheral site, such as the upper respiratory tract, blood or stools; specimens from these 
sites should, therefore, also be routinely tested in infants with suspected meningitis (14). 
Rapid diagnosis will help rationalise antimicrobial use, guide additional investigations, 
support early hospital discharge and reassure parents about long-term outcomes (15,16).  
 
The finding that nearly 10% of cases were diagnosed within the first week of life, without 
any particular association with EV/HPeV type, suggests transplacental transmission in this 
cohort because of the relatively short interval between birth and illness; transplacental 
transmission has been demonstrated in a previous prospective cohort study which 
identified echovirus 11  from the respiratory or gastrointestinal tract of 4 out of 7 infected 
neonates by three days of age and also in their mothers at term (17). The lack of CSF 
pleocytosis in half the cases has been reported in the literature but is not widely known 
among clinicians and microbiologists. In a recent, retrospective South Korean study 
involving 390 children with EV meningitis, 16-18% did not have CSF pleocytosis, but this 
proportion increased to 68-77% in neonates; young age, lower peripheral WBC count and 
shorter interval between illness onset and lumbar puncture were associated with the 
absence of CSF pleocytosis (18). Our study highlights the importance of performing lumbar 
punctures in unwell young infants with non-specific presentations and routinely testing for 
EV/HPeV in the CSF and other sites.  
 
Viral meningitis is generally associated with good outcomes but there is a paucity of robust 
follow-up data for infants. We, for the first time, are able to reliably estimate the low but 
significant risk of serious outcomes in young infants with EV/HPeV meningitis, supporting 
some of the previous studies (19) (20), although others have reported no (21–23) or only 
mild (24) complications at follow-up. Most of these studies were conducted >20 years ago, 
used crude developmental assessment tools at inconsistent times after the acute illness and 
evaluated small numbers of infants. Notably, in our cohort, although only 38% of infants 
underwent audiological testing after hospital discharge, none had hearing loss, which is in 
keeping with another recent UK national surveillance of 106 infants with HPeV and supports 
current consensus that audiological follow up after hospital discharge in infants with EV and 
HPeV meningitis is not routinely required in infants who are otherwise well at hospital 
discharge (25).  
 
HPeV represented a small proportion of our cases, partly because HPeV infections peak 
every two years and this study was conducted in a year of low HPeV activity (4,26,27). 
Additionally, many hospital laboratories still do not routinely test for HPeV, even those that 
routinely test for EV, although an increasing number of hospital laboratories have been 
adding HPeV testing to their existing multiplex PCR assays recently (28).  
 
Several studies have reported significant long-term neurodevelopmental sequelae in infants 
with HPeV meningitis, especially associated with HPeV type 3 (29) (30). These studies, 
however, often reported a small and highly selective group of infants with very severe 
clinical presentations, but they do highlight the potential for this virus to cause permanent 
irreversible neurological damage. These results also question whether those with less 
severe clinical presentations might go on to develop subtle long-term complications that 
remain undetected. 
 
Additional robust long-term neurodevelopmental studies with larger numbers of cases are 
required to provide an evidence base for management of infants with viral meningitis 
beyond hospital discharge.  
 
The strength of this study lies in the prospective national surveillance that captured all cases 
across the UK and Ireland over a relative short time period. A limitation of our study is the 
low proportion of EV/HPeV strains submitted for typing to the PHE reference laboratory 
(31); we were, therefore, unable to assess correlations between serotype and poor 
outcomes, which were rare. Additionally, as there are no currently no evidence-based 
guidelines, clinical investigations and management as well as outpatient follow-up of infants 
was haphazard, with only 30% of infants reviewed after hospital discharge. It is, therefore, 
possible that our estimate of long-term complications may be underestimated 
  
In conclusion, the incidence of laboratory-confirmed EV/HPeV meningitis in young infants is 
more than twice that for bacterial meningitis in the UK and Ireland. Around 1% of infants 
will develop significant complications or die of their infection. Further studies are required 
to determine long-term neurodevelopmental sequelae in infants who are well at hospital 
discharge. Clinicians should consider formal neurodevelopmental assessment in infants with 
persistent symptoms, and those with severe neurological presentations and/or abnormal 
neuroimaging findings during the acute illness.  
 
What’s known on this subject:  
 Enterovirus and human parechovirus are common causes of infant meningitis.  
 The clinical burden of disease is unknown due to a lack of robust epidemiological 
data.  
 No antiviral or vaccines are licenced in Europe or the USA to treat or prevent 
disease. 
 
What this study adds:  
 In UK infants, the combined incidence of EV (0.79/1,000 live-births) and HPeV 
(0.04/1,000 live-births) meningitis is more than double that for bacterial meningitis 
 More than half the infants had absent CSF pleocytosis and low inflammatory 
markers.  
 Less than 1% of infants developed significant complications or died of their infection. 
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Parameter Definition  
Early-onset 0-6 days 
Late-onset 7-89 days 
Preterm <37 weeks gestation 
Term ≥37 weeks 
CSF pleocytosis >20 white cells per mm3(32) 
Features of circulatory shock included any combination of hypotension, mottled skin, 
capillary refill time >2 seconds, tachycardia >160 beats/min and/or reduced urinary 
output <2mls/kg/hr. 
 
Table 1: Definitions of demographic and clinical parameters  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Age at diagnosis  
 0-6 days 7 – 28 days 29 – 89 days All cases 
Virus: 
EV 
HPeV 
 
64 (91) 
6 (9) 
 
207 (94) 
13 (6) 
 
372 (96) 
15 (4) 
 
643 (95) 
34 (5) 
Site of admission: 
PICU 
HDU 
Ward 
PAU 
 
29 (42) 
5 (7) 
35 (51) 
0 
 
16 (7) 
15 (7) 
169 (74) 
29 (13) 
 
7 (2) 
12 (3) 
335 (86) 
34 (9) 
 
52 (8) 
32 (4) 
539 (79) 
63 (9) 
Clinical 
presentation: 
Fever 
Irritability 
Lethargy 
Reduced feeding 
Respiratory 
distress 
 
 
49 (68) 
26 (36) 
33 (45) 
35 (49)  
19 (26) 
 
 
186 (83) 
146 (65) 
88 (39) 
121 (54) 
32 (14) 
 
 
342 (90) 
277 (73) 
130 (34) 
211 (55) 
23 (6) 
 
 
577 (34) 
449 (26) 
251 (15) 
367 (21) 
74 (4) 
 
Laboratory 
findings: 
WCC 
Neutrophil 
CRP 
CSF WCC 
 
10.3 (8.0 – 
14.7) 
6.8 (4 – 10.7) 
14 (5 – 25) 
6 (2 – 32)  
 
9.8 (3.9 – 20.8) 
4.6 (3.5 – 6.8) 
11 (4 – 22) 
8 (2 – 102) 
 
9.3 (7.2 – 12) 
4.1 (2.9 – 6) 
8 (3.9 – 16.8) 
26 (2 – 122) 
 
9.8 
5.1 
11 
9 
Outcome at 
discharge: 
Recovered 
Sequale 
Died 
 
 
65 (97) 
2 (3) 
0 
 
 
202 (98) 
3 (1) 
2 (1) 
 
 
340 (98) 
8 (2) 
0 
 
 
607 (98) 
13 (2) 
2 (0) 
Serotype 
Coxsackie B4 
Coxsackie B5 
Echovirus 7 
Echovirus 9 
Echovirus 11 
Echovirus 18 
Echovirus 25 
Echovirus 30  
Enterovirus 71 
Untyped 
 
4 (10) 
1 (2) 
3 (7) 
9 (22) 
4 (10) 
4 (10) 
3 (7) 
1 (2) 
1 (2) 
5 (12) 
 
8 (6) 
11 (8) 
12 (9) 
18 (13) 
3 (2) 
13 (9) 
4 (3) 
7 (5) 
10 (7) 
33 (24) 
 
16 (6) 
20 (7) 
24 (9) 
48 (18) 
12 (4) 
26 (10) 
18 (7) 
9 (3) 
6 (2) 
55 (21) 
 
28 (7) 
32 (8) 
39 (10) 
75 (20) 
19 (5) 
43 (12) 
25 (6) 
17 (4) 
17 (4) 
93 (24) 
Data are presented as numbers of cases (%) 
 
Table 2: Characteristics of infants aged <90 day with EV and HPeV meningitis in the United 
Kingdom and Ireland during July 2014 to July 2015 inclusive 
EV= enterovirus;  HPeV = Human parechovirus;  PICU = Paediatric intensive Care Unit; HDU = 
High Dependency unit;  PAU=Paediatric Assessment Unit;   CSF = Cerebrospinal fluid; WCC = 
white cell count; CRP = C reactive protein 
 
 Presenting features Admission to Intensive 
Care  
Neuroimaging findings Outcome at hospital 
discharge 
Outcome at 12 months 
EV deaths      
Born at term  
<1 week old  
EV11 infection 
Afebrile, lethargic, 
reduced feeding; 
developed multi-organ 
failure and shock. CRP 
6, CSF WCC clotted 
Intubated & ventilated 
(13 d), inotropes (12 
d); IV corticosteroids + 
IVIG  
Cranial ultrasound scan 
normal; echocardiogram – 
mitral valve regurgitation 
and valvulitis 
Died after 2 weeks of 
massive pulmonary 
haemorrhage 
 
Born at term  
1 month  
EV (not typed) 
Reduced feeding; 
circulatory collapse; 
rapid deterioration 
CRP 52; CSF WCC 0 
 
Intubated & ventilated 
(1 d), inotropes (1 d)  
Not performed Died within 48 hours; 
EV isolated from heart 
and brain tissue at post 
mortem 
 
EV sequelae      
Premature (33-36 wks)  
1 month old  
EV11 infection 
Respiratory distress, 
apnoea 
CRP 4.6, CSF WCC 0 
Intubated & ventilated 
(1 d), inotropes (2 d), 
haemofiltration (1d) 
MRI: diffuse encephalitis 
and microcephaly. 
Reduced tone trunk, 
increased tone in the 
limbs 
Reduced vision, reduced 
truncal tone, increased tone 
in the limbs; seizures 
Born at term 
<1 week old 
Coxsackie B4 infection 
Fever, irritability, 
respiratory distress, 
bulging fontanelle, 
cardiovascular shock 
CRP 45, CSF WCC 20 
Intubated & ventilated 
(35 d) ionotropic 
support; 1 dose IVIG 
MRI: acute infarction, right 
anterior corona  
Poor ventricular 
function requiring 
medical treatment 
Poor ventricular function, 
on captopril  
HPeV sequelae      
Born at term 
1 week old 
HPeV (not typed) 
Irritability poor 
feeding, respiratory 
distress, signs of shock 
CRP 8, CSF WCC 2 
Not admitted  Not performed  Transaminitis (normal 
abdominal ultrasound) 
at discharge  
Well 
12 month follow-up      
Premature (28-32 wks) 
1 month old 
EV (not typed) 
Lethargy, reduced 
feeding, apnoea  
CRP 5, CSF WCC 13 
Intubated & ventilated 
(5 d), 
MRI: severe cystic 
encephalomalacia, multiple 
fluid filled cysts in frontal, 
parietal & temporal lobes  
No clinical symptoms 
or signs 
Seizures controlled on anti-
epileptics 
Born at term 
1 week old 
EV (not typed) 
Fever, irritability, rash, 
seizure; CRP 99; CSF 
WCC 90 
Not admitted  Cranial ultrasound normal Well at discharge  Tonic clonic seizures; not on 
regular anticonvulsants 
Table 3. Death and Sequelae among infants aged <90 days with enterovirus (EV) and human parechovirus (HPeV) meningitis in the United 
Kingdom and Ireland during July 2014 to July 2015 inclusive. IVIG, intravenous immunoglobulin; CRP, c-reactive protein.mg/dl; CSF WCC, 
cerebrospinal fluid white cell count/per mm3;  
 
